Search research articles
Contact Us
Filters
Showing results (91-100 of 96) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 96 results.
Leukemia
|
November 14, 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.
Blood
|
May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy
Nicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2019
Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
Linus Angenendt, Christoph Röllig, Pau Montesinos, et al.
Cancer Discovery
|
April 3, 2023
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia
Marie Sabatier, Rudy Birsen, Laura Lauture, et al.
Leukemia
|
October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 96) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 96 results.
Leukemia
|
November 14, 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.
Blood
|
May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy
Nicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2019
Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
Linus Angenendt, Christoph Röllig, Pau Montesinos, et al.
Cancer Discovery
|
April 3, 2023
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia
Marie Sabatier, Rudy Birsen, Laura Lauture, et al.
Leukemia
|
October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.
Page
of 10